{"No": [0], "treatment": [1], "has": [2], "surpassed": [3], "platinum-based": [4, 54], "chemotherapy": [5, 55, 166, 195, 264, 292, 306], "in": [6, 10, 56, 71, 187, 193, 251, 262, 275, 280, 286, 290, 301, 307, 324, 343], "improving": [7], "overall": [8, 147, 221], "survival": [9, 138, 179, 184, 222], "patients": [11, 57, 153, 279, 308], "with": [12, 48, 58, 295, 309, 317, 322], "previously": [13, 59], "untreated": [14, 60, 310], "locally": [15, 61, 311], "advanced": [16, 62, 312], "or": [17, 63, 114, 119, 208, 272, 313], "metastatic": [18, 64, 314], "urothelial": [19, 65, 315], "carcinoma.": [20, 66], "Download": [21], "a": [22, 30, 72, 83, 102, 318], "PDF": [23], "of": [24, 43, 53, 79, 85, 90, 104, 125, 151, 169, 176, 243, 269, 277, 288], "the": [25, 39, 49, 123, 158, 165, 173, 188, 194, 252, 263, 278, 281, 291], "Research": [26], "Summary.": [27], "We": [28], "conducted": [29], "phase": [31], "3,": [32], "global,": [33], "open-label,": [34], "randomized": [35], "trial": [36], "to": [37, 75, 127, 157, 164, 216, 237, 249, 260], "compare": [38], "efficacy": [40, 50], "and": [41, 46, 51, 97, 99, 116, 146, 162, 256, 285, 298, 332], "safety": [42, 52, 319], "enfortumab": [44, 80, 159, 189, 253, 282, 296], "vedotin": [45, 81, 297], "pembrolizumab": [47, 100, 299], "Patients": [67], "were": [68, 136], "randomly": [69], "assigned": [70], "1:1": [73], "ratio": [74, 204, 230], "receive": [76, 128], "3-week": [77], "cycles": [78, 244], "(at": [82, 101], "dose": [84, 103], "1.25": [86], "mg": [87, 106], "per": [88], "kilogram": [89], "body": [91], "weight": [92], "intravenously": [93, 107], "on": [94, 108, 122], "days": [95], "1": [96, 248, 259], "8)": [98], "200": [105], "day": [109], "1)": [110], "(enfortumab": [111], "vedotin\u2013pembrolizumab": [112, 160, 190, 254, 283], "group)": [113], "gemcitabine": [115], "either": [117], "cisplatin": [118], "carboplatin": [120], "(determined": [121], "basis": [124], "eligibility": [126], "cisplatin)": [129], "(chemotherapy": [130], "group).": [131], "The": [132, 240], "primary": [133], "end": [134], "points": [135], "progression-free": [137], "as": [139, 219], "assessed": [140], "by": [141, 328], "blinded": [142], "independent": [143], "central": [144], "review": [145], "survival.": [148], "A": [149], "total": [150], "886": [152], "underwent": [154], "randomization:": [155], "442": [156], "group": [161, 191, 196, 255, 284], "444": [163], "group.": [167, 265, 293], "As": [168], "August": [170], "8,": [171], "2023,": [172], "median": [174, 241], "duration": [175], "follow-up": [177], "for": [178, 205, 231], "was": [180, 185, 220, 245], "17.2": [181], "months.": [182], "Progression-free": [183], "longer": [186], "than": [192, 305], "(median,": [197, 223], "12.5": [198], "months": [199, 225], "vs.": [200, 226], "6.3": [201], "months;": [202, 228], "hazard": [203, 229], "disease": [206], "progression": [207], "death,": [209, 232], "0.45;": [210], "95%": [211, 234], "confidence": [212], "interval": [213], "[CI],": [214], "0.38": [215, 236], "0.54;": [217], "P<0.001),": [218], "31.5": [224], "16.1": [227], "0.47;": [233], "CI,": [235], "0.58;": [238], "P<0.001).": [239], "number": [242], "12": [246], "(range,": [247, 258], "46)": [250], "6": [257], "6)": [261], "Treatment-related": [266], "adverse": [267], "events": [268], "grade": [270], "3": [271], "higher": [273], "occurred": [274], "55.9%": [276], "69.5%": [287], "those": [289], "Treatment": [294], "resulted": [300], "significantly": [302], "better": [303], "outcomes": [304], "carcinoma,": [316], "profile": [320], "consistent": [321], "that": [323], "previous": [325], "reports.": [326], "(Funded": [327], "Astellas": [329], "Pharma": [330], "US": [331], "others;": [333], "EV-302": [334], "ClinicalTrials.gov": [335], "number,": [336], "NCT04223856.)": [337], "QUICK": [338], "TAKE": [339], "VIDEO": [340], "SUMMARYEnfortumab": [341], "Vedotin\u2013Pembrolizumab": [342], "Advanced": [344], "Urothelial": [345], "Cancer": [346], "02:22": [347]}